MARKET

LEGN

LEGN

Legend Biotech Corp
NASDAQ
28.60
-0.07
-0.24%
After Hours: 28.30 -0.3 -1.05% 19:31 05/14 EDT
OPEN
28.50
PREV CLOSE
28.67
HIGH
29.33
LOW
27.90
VOLUME
2.22M
TURNOVER
--
52 WEEK HIGH
45.30
52 WEEK LOW
16.24
MARKET CAP
5.31B
P/E (TTM)
-21.0899
1D
5D
1M
3M
1Y
5Y
1D
Legend Biotech (LEGN) Q1 Loss Persists And Tests Bullish Profitability Narratives
Simply Wall St · 1d ago
These Analysts Revise Their Forecasts On Legend Biotech After Q1 Results
Benzinga · 1d ago
Legend Biotech Price Target Raised to $29.00/Share From $21.00 by TD Cowen
Dow Jones · 1d ago
Legend Biotech Is Maintained at Hold by TD Cowen
Dow Jones · 1d ago
TD Cowen Maintains Hold on Legend Biotech, Raises Price Target to $29
Benzinga · 1d ago
Legend Biotech Price Target Cut to $48.00/Share From $49.00 by Morgan Stanley
Dow Jones · 1d ago
Legend Biotech Is Maintained at Overweight by Morgan Stanley
Dow Jones · 1d ago
Legend Biotech price target lowered to $48 from $49 at Morgan Stanley
TipRanks · 1d ago
More
About LEGN
Legend Biotech Corporation is a global biopharmaceutical company. The Company is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.

Webull offers Legend Biotech Corp (ADR) stock information, including NASDAQ: LEGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LEGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LEGN stock methods without spending real money on the virtual paper trading platform.